Combined treatment with etanercept 50 mg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasis

European Journal of Dermatology

Volumn 21, Issue 4, 2011, Pages 568-572

  De Simone, Clara ^a   D'Agostino, Magda ^a   Capizzi, Rodolfo ^a   Capponi, Angela ^b   Venier, Antonio ^a   Caldarola, Giacomo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Etanercept; NB UVB; Psoriasis

Indexed keywords

ETANERCEPT;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; COST OF ILLNESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ERYTHEMA; FEMALE; HUMAN; INJECTION SITE REACTION; LOW DRUG DOSE; MALE; OUTCOME ASSESSMENT; PHOTOTHERAPY; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; RADIATION DOSE; RADIATION INJURY; SCORING SYSTEM; THERAPY EFFECT; ULTRAVIOLET B RADIATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; ULTRAVIOLET THERAPY;

EID: 80053012581     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2011.1330     Document Type: Article

References (34)

1. de Rie MA, Goedkoop AY, Bos JD. Overview of psoriasis. Dermatol Ther 2004; 17: 341-9.
2. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-7.
3. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 S2: 1-70.
4. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019.
5. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-22.
6. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304-12.
7. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebocontrolled randomised phase III trial. Lancet 2006; 367: 29-35.
8. Ellis CN, Fradin MS, Messana JM, et al. Cyclosporine for plaque psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991; 324: 277-8.
9. Melski JW, Tannenbaum L, Parrish JA. Oral methoxalen photochemotherapy for the treatment of psoriasis a cooperative clinical trial. J Invest Dermatol 1977; 68: 328-35.
10. Stein KR, Pearce DJ, Feldman SR. The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Semin Cutan Med Surg 2005; 24: 52-7.
11. Hönigsmann H. Phototherapy for psoriasis. Clin Exp Dermatol 2001; 26: 343-50.
12. Feldman SR, Evans C, Russell MW. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan. J Dermatolog Treat 2005; 16: 37-42.
13. Gupta G, Long J, Tillman DM. The efficacy of narrowband ultraviolet B phototherapy in psoriasis using objective and subjective outcome measures. Br J Dermatol 1999; 140: 887-90.
14. Nguyen T, Gattu S, Pugashetti R, Koo J. Practice of phototherapy in the treatment of moderate-to-severe psoriasis. Curr Probl Dermatol 2009; 38: 59-78.
15. Di Lernia V, Albertini G. Is antitumour necrosis factor therapy combined with ultraviolet B phototherapy safe?. Br J Dermatol 2010; 162: 1147-8.
16. Kircik L, Bagel J, Korman N, et al. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. J Drugs Dermatol 2008; 7: 245-53.
17. Sminkels OQ, Prins M, Veeniiuis RT, et al. Effectiveness and side effects of UVB-phototherapy, dithranol inpatient therapy and a care instruction programme of short contact dithranol in moderate to severe psoriasis. Eur J Dermatol 2004; 14: 159-65.
18. Wolf P, Hofer A, Legat FJ, et al. Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept. Br J Dermatol 2009; 160: 186-9.
19. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
20. Katugampola RP, Lewis VJ, Finlay AY. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol 2007; 156: 945-50.
21. Wainwright NJ, Dawe RS, Ferguson J. Narrowband UVB (TL-o1) phototherapy for psoriasis: which incremental regimen? Br J Dermatol 1998; 139: 410-4.
22. Legat FJ, Hofer A, Wackernagel A, et al. Narrowband UV-B phototherapy, alefacept, and clearance of psoriasis. Arch Dermatol 2007; 143: 1016-22.
23. Ortonne JP, Khemis A, Koo JY, Choi J. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2005; 19: 556-63.
24. Jacobe H, Winterfield L, Kim F, Huet-Adams B, Cayce R. The role of narrowband UV-B plus alefacept combination therapy in the treatment of psoriasis. Arch Dermatol 2008; 144: 1067-8.
25. Koo JY, Bagel J, Sweetser MT, Ticho BS. Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study. J Drugs Dermatol 2006; 5: 623-8.
26. Zane C, Capezzera R, Venturini M, et al. A short cycle of narrowband UVB phototherapy in the early phase of long-term efalizumab can provide a quicker remission of moderate and severe psoriasis: a pilot study. Dermatology 2009; 218: 321-6.
27. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-74.
28. Nelson AA, Pearce DJ, Fleischer AB Jr., Balkrishnan R, Feldman SR. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol 2008; 58: 125-35.
29. Stein KR, Pearce DJ, Feldman SR. The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Semin Cutan Med Surg 2005; 24: 52-7.
30. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005; 32: 2130-5.
31. Chakravarty EF, Farmer ER. Risk of skin cancer in the drug treatment of rheumatoid arthritis. Expert Opin Drug Saf 2008; 7: 539-46.
32. el-Ghorr AA, Norval M. Biological effects of narrow-band (311 nm TL01) UVB irradiation: a review. J Photochem Photobiol B 1997; 38: 99-106.
33. Hallaji Z, Barzegari M, Balighi K, et al. A comparison of three times vs. five times weekly narrowband ultraviolet B phototherapy for the treatment of chronic plaque psoriasis. Photodermatol Photoimmunol Photomed. 2010; 26: 10-5.
34. Reich K, Segaert S, Van de Kerkhof P, et al. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. Dermatology 2009; 219: 239-49.